Arrowstreet Capital
KIN

Arrowstreet Capital’s Kindred Biosciences, Inc. KIN Stock Holding History

Arrowstreet Capital’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,000
Closed -$51K – 2621
2020
Q3 		$51K Sell
12,000
-15,300
-56% -$63.9K ﹤0.01% 2283
2020
Q2 		$123K Buy
+27,300
New +$122K ﹤0.01% 2207

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's KIN Position: Q4 2020 in Review

Arrowstreet Capital sold out of Kindred Biosciences, Inc. (KIN) in Q4 2020, closing a stake of 12,000 shares — an estimated $51K sold.

Arrowstreet Capital first reported a position in KIN in Q2 2020 and held it in 2 quarters. The position peaked at $123K in Q2 2020. 82 funds tracked by Wall St. Rank hold KIN as of Q4 2020.

  • Arrowstreet Capital reported no remaining Kindred Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 12,000 Kindred Biosciences, Inc. shares in Q4 2020, an estimated $51K.
  • Arrowstreet Capital first reported a position in Kindred Biosciences, Inc. in Q2 2020 and held it in 2 quarters.
  • Arrowstreet Capital's Kindred Biosciences, Inc. position peaked at $123K in Q2 2020.
  • 82 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.